Pure Global

Clinical Trial - Trial ChiCTR2100053602

Access comprehensive clinical trial information for ChiCTR2100053602 through Pure Global AI's free database. This Phase 4 trial is sponsored by Ruijin Hospital, Shanghai Jiaotong University School of Medicine and is currently Not yet recruiting. The study focuses on Hepatitis B.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
ChiCTR2100053602
Phase 4
Not yet recruiting
Trial Details
Chinese Clinical Trial Registry • ChiCTR2100053602
View on Chinese Clinical Trial Registry
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Untitled Trial
Efficacy and safety of amtenofovir in patients with ALT normal chronic hepatitis B infection: a prospective, randomized, blank-controlled, multicenter clinical study

Study Focus

Hepatitis B

Patients meeting the admission criteria were randomly assigned to group A or group B: Group A (TMF treatment group): from day 1 of week 1, orally, once A day, 25mg each time, 133 patients were expected to be enrolled; Group B (blank control group): 133 patients were expected to be enrolled as blank control group without any antiviral treatment.

Sponsor & Location

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Supported by Jiangsu Hausen Pharmaceutical Group Co., LTD

China

Timeline & Enrollment

Phase 4

N/A

Nov 26, 2024

ICD-10 Classifications

Acute hepatitis B
Acute hepatitis B without delta-agent and without hepatic coma
Acute delta-(super)infection in chronic hepatitis B
Chronic viral hepatitis B without delta-agent
Chronic viral hepatitis B without delta-agent : other and unspecified phase

Data Source

Chinese Clinical Trial Registry

ChiCTR2100053602

Non-Device Trial